Nexalis plots capital raise as search goes on for new funding partner by Steve Jones November 3, 2026November 3, 2026 Cannabinoid drug development firm Nexalis Therapeutics is planning a capital raise to relieve the pressure on […]
Cannabis executive salaries: who earned what in FY26 by Adam Sheldon October 15, 2026October 19, 2026
Nexalis trials still on hold as directors ponder revision of clinical program by Steve Jones August 1, 2026August 5, 2026
Replacement funding falls through as Nexalis studies remain suspended by Adam Sheldon July 6, 2026July 9, 2026
Nexalis suspends trial projects after funding partner withdraws support by Steve Jones June 1, 2026June 1, 2026
News in brief: Judgment reserved in CDA Clinics QLD legal case; Nexalis completes Phase 1 IRX-616a dosing by Adam Sheldon May 18, 2026June 8, 2026
News in brief: Nexalis advances IRX-616a and IRX-211 programs; Vitura heralds Doctors on Demand growth; Elixinol improves cash flow by Adam Sheldon April 20, 2026June 11, 2026
